TG Therapeutics announces publication describing complimentary mechanism of TGR-1202
TG Therapeutics announced publication in Blood of preclinical data describing synergy of Company's next generation, once daily, PI3K-delta inhibitor, TGR-1202, with the proteasome inhibitor carfilzomib to silence c-Myc in various preclinical lymphoma and myeloma models. October 27, 2016